PIPELINE
We make MYC-driven cancers tractable by advancing MYC synthetic lethality as a new class of precision oncology therapeutics
- First-in-class and pioneering MYC-synthetic lethal MKLP2 inhibitors in trials.
- Multiple synergistic tumor-suppressing mechanisms of action (MOAs): MYC-SL, antiangiogenesis, TIME remodeling.
- Biomarker-driven clinical strategy: mechanism-directed predictive and PD biomarkers.
- Distinct characteristics of pipeline candidates: molecular design, PK profiles, tissue specificity, and MOA sophistication.
CLINICAL DEVELOPMENT PIPELINE
DRUG
INDICATIONS
MYC+ solid tumors and lymphomas
PROGRESS
PRE-
CLINICAL
CLINICAL
IND
PHASE 1
PHASE 2
PHASE 3
DRUG
JMBI-003
INDICATIONS
MYC+ solid tumors and lymphomas
PROGRESS
PRE-
CLINICAL
CLINICAL
IND
PHASE 1
PHASE 2
PHASE 3
DRUG
JMBI-002
INDICATIONS
MYC+ solid tumors and lymphomas
PROGRESS
PRE-
CLINICAL
CLINICAL
IND
PHASE 1
PHASE 2
PHASE 3
DRUG
JMBI-204
INDICATIONS
MYC+ solid tumors and lymphomas
PROGRESS
PRE-
CLINICAL
CLINICAL
IND
PHASE 1
PHASE 2
PHASE 3
DRUG
JMBI-205
INDICATIONS
MYC+ solid tumors and lymphomas
PROGRESS
PRE-
CLINICAL
CLINICAL
IND
PHASE 1
PHASE 2
PHASE 3